

Computer-Aided Detection of Colorectal Polyps at CT Colonography: Prospective Clinical Performance and Third-Party Reimbursement

Timothy J. Ziemlewicz¹
David H. Kim
J. Louis Hinshaw
Meghan G. Lubner
Jessica B. Robbins
Perry J. Pickhardt

Keywords: colonography, computer-aided detection, CT, polyps, screening

DOI:10.2214/AJR.16.17499

Received October 1, 2016; accepted after revision November 28, 2016.

D. H. Kim is a cofounder of VirtuoCTC and a consultant for Viatronix and serves on the medical advisory board for Digital Artforms. M. G. Lubner receives research funding from GE Healthcare, Neuwave Medical, and Philips Healthcare. P. J. Pickhardt is a cofounder of VirtuoCTC and a shareholder in Collectar Biosciences, Elucient, and SHINE.

Based on a presentation at the Radiological Society of North America 2016 annual meeting, Chicago, IL.

¹All authors: Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, MC 3252, Madison, WI 53792. Address correspondence to T. J. Ziemlewicz (tziemlewicz@uwhealth.org).

AJR 2017; 208:1244–1248

0361–803X/17/2086–1244

© American Roentgen Ray Society

OBJECTIVE. We assessed the initial clinical performance and third-party reimbursement rates of supplementary computer-aided detection (CAD) at CT colonography (CTC) for detecting colorectal polyps 6 mm or larger in routine clinical practice.

MATERIALS AND METHODS. We retrospectively assessed the prospective clinical performance of a U.S. Food and Drug Administration–approved CAD system in second-reader mode in 347 consecutive adults (mean age, 57.6 years; 205 women, 142 men) undergoing CTC evaluation over a 5-month period. The reference standard consisted of the prospective interpretation by experienced CTC radiologists combined with subsequent optical colonoscopy (OC), if performed. We also assessed third-party reimbursement for CAD for studies performed over an 18-month period.

RESULTS. In all, 69 patients (mean [\pm SD] age, 59.0 \pm 7.7 years; 32 men, 37 women) had 129 polyps \geq 6 mm. Per-patient CAD sensitivity was 91.3% (63 of 69). Per-polyp CAD-alone sensitivity was 88.4% (114 of 129), including 88.3% (83 of 94) for 6- to 9-mm polyps and 88.6% (31 of 35) for polyps 10 mm or larger. On retrospective review, three additional polyps 6 mm or larger were seen at OC and marked by CAD but dismissed as CAD false-positives at CTC. The mean number of false-positive CAD marks was 4.4 \pm 3.1 per series. Of 1225 CTC cases reviewed for reimbursement, 31.0% of the total charges for CAD interpretation had been recovered from a variety of third-party payers.

CONCLUSION. In our routine clinical practice, CAD showed good sensitivity for detecting colorectal polyps 6 mm or larger, with an acceptable number of false-positive marks. Importantly, CAD is already being reimbursed by some third-party payers in our clinical CTC practice.

CT colonography (CTC) is a well-validated method for colorectal cancer screening and has recently been added to the United States Preventive Services Task Force (USPSTF) guidelines [1, 2]. This addition stands to increase adoption of CTC in the radiology community. As with any screening program, the sensitivity for detecting precancerous lesions is paramount to prevent malignancy and associated impact. This need has led to interest in computer-aided detection (CAD) as a supplement to human readers to increase the sensitivity of examinations. CAD has been shown to have high sensitivity as a stand-alone reader for polyps 10 mm or larger as well as increasing the sensitivity of human readers for 6- to 9-mm polyps [3–8].

Multiple retrospective series, simulated multireader evaluations of standardized sets, and even prospective trials have been

used to evaluate CAD in CTC [3–12]. However, there is a lack of data on use of CAD in routine clinical practice. In addition, although the cost-effectiveness of CAD within a screening population has been shown, to our knowledge no data related to the reimbursement of CAD are available [13]. Widespread adoption of CAD beyond academic centers likely demands that it be reimbursed to justify additional costs and time. The purpose of this study is to report the clinical performance of CAD as prospectively recorded during standard CTC workflow, with a secondary aim to evaluate third-party reimbursement stemming from routine clinical use.

Materials and Methods

This retrospective study was performed under a waiver of informed consent from our institutional review board. Data collection was performed in compliance with HIPAA requirements.

CAD of Colorectal Polyps at CTC

Patient Population

Asymptomatic adults undergoing routine screening CTC in a single health care system over a 5-month period formed the initial study population of 393 patients. CAD failed to build on at least one series in 41 patients. Patients had all marks identified by CAD recorded by the interpreting radiologist in a clinical database. Marks were not recorded for five patients for unknown reasons. A total of 347 patients were included in the final analysis (Fig. 1).

CT Colonography Technique

We employed a standard CTC technique described in detail elsewhere [1, 14–16]. Patients undergo a bowel preparation protocol beginning 1 day before CTC consisting of complete colonic catharsis and tagging of residual material. The cathartic cleansing agent was magnesium citrate; polyethylene glycol was substituted as needed in a small number of patients. Contrast material tagging of residual fluid and fecal material was achieved with 2.1% weight/volume barium and diatrizoate (Gastrografin, Bracco). During the CTC examination, colonic insufflation was achieved and maintained throughout image acquisition using automated continuous carbon dioxide delivered through a rectal catheter [17]. Patients were routinely scanned in both supine and prone positions with decubitus positioning as needed [18]. Images were acquired with 8- to 64-MDCT scanners using 1.25-mm collimation, a 1-mm reconstruction interval, 120 kVp, and tube current modulation (range, 30–300 mA).

CT interpretation was performed for both the supine and prone (as well as decubitus in 45 patients) positions on a V3D workstation (Viatronix) with a combined 2D read for evaluation of the pooled fluid and 3D read as the means of primary polyp detection. For cases in which more than two series were created, the two with greatest luminal distention were used for luminal, and therefore CAD, evaluation. Initially, a primary read was performed by one of six abdominal radiologists (2–10 years' experience with CTC). At the completion of the primary human read, CAD (Veralook version 1.0, iCAD) was applied in the second-reader mode. The CAD-identified marks (i.e., potential lesions) were carefully reviewed by the interpreting radiologist using 2D or 3D images (or both). At the time of image analysis, the interpreting radiologist recorded the number of CAD marks in each position and whether they were thought to be true-positives or false-positives. To be considered a true-positive CAD result, at least a portion of the lesion had to be seen within the ROI of the 2D mark (Fig. 2). Findings from optical colonoscopy (OC), pathologic evaluation, or both, if done, were also incorporated into all applicable cases. A subset of the CAD recordings included a determination of a cause for each false-positive CAD recording.

Reference Standard and the Computer-Aided Detection System

In all cases, initial interpretation by the radiologist served as the reference standard. Of the 69 patients with positive CTC findings, 45 were

also evaluated with subsequent OC and one underwent surgery after discovery of a colonic mass. All of the polyps measuring 6 mm or larger found at OC, regardless of CTC detection, were recorded; the corresponding CTC was reviewed for re-

Fig. 1—Participant diagram.





Fig. 2—65-year-old man with 7-mm sessile polyp identified at screening CT colonography (CTC). **A**, Three-dimensional colon map shows location of polyp in descending colon (red dot adjacent to blue arrow). **B**, Three-dimensional endoluminal rendering showing computer-assisted detection (CAD) mark (blue) of polyp. Yellow arrow and green line are function of software. **C**, Prone transverse CTC image with yellow ROI around blue marked polyp (arrow); both markings are from CAD program. **D**, Optical colonoscopy image of polyp before retrieval. Polyp was tubular adenoma at histopathology.

confirmation. The remaining 23 patients did not undergo optical colonoscopy either because their polyps were classified as CT Colonography Reporting and Data System category C2 and the patients elected 3-year CTC follow-up or because the patient had not yet undergone optical colonoscopy (two patients) [19, 20]. OC was attempted with no polyp identified in one patient with positive CTC findings. This case was reviewed in consensus by two additional radiologists who confirmed the presence of a polyp. This patient was scheduled to undergo a repeat OC [21].

With respect to the reference standard, CTC cases with at least one true-positive, one false-negative, or both types of CAD hits were regarded as positive for true polyps. The per-polyp and per-patient sensitivities of CAD polyp detection were calculated according to these stratifications.

Reimbursement Evaluation

In an expanded population of 1225 patients consecutively enrolled over an 18-month period, billing data were searched for Current Procedural Terminology code 76497 to identify cases in which CAD was used and a \$30 charge applied. The volume, total charges, and balance of reimbursement from all private and public payers were recorded for this cohort.

Data and Statistical Analysis

Means, SDs, and sensitivities were calculated using Excel (version 2010, Microsoft).

Results

Computer-Aided Detection Evaluation

The study population consisted of 347 patients (205 women, 142 men) with a mean age of 57.6 years (range, 34–88 years). Of this population, 69 patients (19.9%) had 129 polyps 6 mm or larger identified (Table 1). The mean age of the 37 women and 32 men with positive CTC findings was 59.0 years (range, 39–83 years). Of the 129 colorectal polyps measuring at least 6 mm, 72.9% (94/129) were 6–9 mm and 27.1% (35/129) were 10 mm or more in diameter.

TABLE 1: Polyp Characteristics

Characteristic	Total No.	Largest Polyp Size	
		≥ 10 mm	6–9 mm
No. of patients with a polyp	69	30	39
CTC-identified polyps	129	35	94
CTC-identified polyps detected by CAD	114	31	83
No. of patients undergoing OC	45	27	18
CTC-identified polyps examined with OC	100	34	66
CTC-identified polyps confirmed at OC	89	29	60
Polyps found at OC that were not identified at CTC	6	0	6
CAD-identified polyps found at OC that were dismissed at CTC	3	0	3

Note—CTC = CT colonography, CAD = computer-assisted detection, OC = optical colonoscopy.

Overall per-patient CAD sensitivity was 91.3% (63/69) and per-polyp CAD sensitivity was 88.4% (114 of 129), including 88.6% (83 of 94) for 6- to 9-mm polyps and 88.6% (31 of 35) for polyps 10 mm or larger. Of the 129 detected polyps, 45.0% (58/129) were detected by CAD on two views, and 55% (71/129) on a single view. Of the six additional polyps larger than 6 mm seen at OC but not prospectively identified at CTC, three had been detected by CAD in retrospect but were dismissed as false-positives by the reader (Fig. 3).

The mean number of CAD marks was 8.3 ± 4.9 per study and 4.4 ± 3.1 per series (Table 2). There were 2911 false-positive CAD marks, 1026 of which had a cause recorded. Of these 1026 in 167 patients, stool (28.6%), folds (26.0%), and the ileocecal valve (17.3%) were the most frequent causes of a false-positive finding.

CAD failed to detect 15 (11.6%) of 129 polyps of 6 mm or larger. Of these 15 false-negative CAD polyps, 53.3% (8/15) were flat or subtle lesions, 6.7% (1/15) were a polyp interposed between two luminal folds, and 20% (3/15) were from reasons that were unclear (Table 3).

Reimbursement Evaluation

Out of the 1225 cases within an 18-month interval for reimbursement assessment, 31.0%

of the total charges were recovered. Across all private payers covering CAD, charge recovery ranged from 18.0% to 72.8%.

Discussion

The role of CAD software in the daily performance of CTC is as a second-reader assistive software. Although previous studies have found CAD to be useful as a stand-alone software tool, to our knowledge this is the first report of the prospective use of the software in a clinical CTC practice. The sensitivity and false-positive rate of CAD in second-reader mode during routine CTC reading were acceptable and comparable with prior nonclinical experiences. In addition, several CAD-identified lesions were dismissed by the radiologist but subsequently identified at OC.

TABLE 2: Computer-Assisted Detection Data by Imaging Position

Imaging Position	No. of Hits	Mean \pm SD
Supine	1344	4.0 \pm 3.0
Prone	1536	4.8 \pm 3.2
Decubitus	208	4.8 \pm 2.8
All positions	3088	4.4 \pm 3.1

TABLE 3: False-Negative Computer-Assisted Detection Description

Description	No. of Polyps	Colon Segment				Histology When OC Performed				
		Rectum	Sigmoid	Transverse	Ascending	Hyperplastic or Serrated Polyp	Tubular Adenoma	Tubulovillous Adenoma	Villous Adenoma	No OC
Flat polyp	9	3	3	2	1	3	2	1	1	2
Between folds	3	1	1	0	1	1	1	0	0	1
Adjacent larger polyp	1	1	0	0	0	0	0	0	0	1
Unclear nature	2	0	2	0	0	0	0	0	0	2

Note—OC = optical colonoscopy.

CAD of Colorectal Polyps at CTC




Fig. 3—67-year-old woman who underwent optical colonoscopy for cecal polyp.
A, Additional flat polyp (*arrow*) was identified in ascending colon at optical colonoscopy. On retrospective evaluation, this polyp was identified by computer-assisted detection (CAD) but dismissed as CAD false-positive by radiologist.
B, Supine transverse CT colonography (CTC) image with flat polyp (*arrow*) within ROI (*blue circle*) from CAD software.
C, Three-dimensional endoluminal rendering of flat polyp.
D, Three-dimensional endoluminal rendering with CAD mark (*blue*) over portion of flat polyp.

Beyond the clinical utility, for any software tool to undergo clinical adoption, monetary factors need to be considered. CTC and the addition of CAD to its interpretation have proven cost-effective [13, 22, 23]. However, some actual recovery from payers, even if only partial, is likely necessary for broad adoption. In the first study, to our knowledge, to evaluate this aspect of the technology, we found a reimbursement rate of 31.0% on charges from a variety of third-party payers for CAD added to routine CTC.

The sensitivity of CAD per patient and per polyp in this study of 91.3% and 88.4%, respectively, is excellent when compared with prior retrospective studies. For example, a 3046-patient cohort retrospectively evaluated with the same software used in this study had per-pa-

tient and per-polyp sensitivities of 93.8% and 90.1% for polyps 6 mm or larger and 96.5% and 96.0% for polyps 10 mm or larger [3]. Another large study of 1689 patients found per-polyp and per-patient CAD sensitivities of 89.0% each for polyps 10 mm or larger [7]. However, compared with our study, the 1689-patient study had lower per-patient and per-polyp sensitivities of 61.3% and 75.8% when evaluating polyps 6 mm or larger.

Increased sensitivity in exchange for decreased specificity is acceptable and warranted when CAD is functioning as a second reader. In fact, a prior study found that use of CAD increases the area under a ROC curve [12]. Many of the false-positive marks related to stool, folds, and the ileocecal valve can be easily excluded by the primary reader with

brief visual examination [24, 25]. The average of 8.3 CAD marks per patient in this study seems to be acceptable. Positive CAD marks may also identify subtle lesions that were either not noted or discounted as unlikely to be a true-positive polyp on initial interpretation. Three nondiminutive polyps were identified at OC that in retrospect were identified by CAD but discarded as a CAD false-positive by the radiologist. The true number of these situations may be larger than reported here, as only 65% of patients with identified polyps went on to OC. Regrettably, none of these additional lesions were recognized as true polyps by the radiologist during real-time CTC interpretation. CAD can be expected to identify more polyps missed by the primary reader when that reader is relatively inexperienced. However, lack of ultimate recognition by the radiologist will result in a missed polyp regardless of CAD detection.

The reimbursement rate in this study of 31% on a standard charge across a variety of payers shows the feasibility of adding CAD to a CTC program. Although the reimbursement on charges of one practice may be difficult to extrapolate to other practices given wide variation in charges for radiologic procedures [26], even partial reimbursement for CAD has important ramifications. Use of CAD for mammography sharply increased after coverage by Medicare and subsequently by many private insurers beginning in 2001, with the prevalence of use in screening mammograms increasing from 3.5% to 79.7% in 2009 [27]. Given the recent USPSTF decision to include CTC in screening guidelines and the evidence that reimbursement for CAD can be obtained in clinical practice, adoption is likely to increase [2].

As computer processing and deep learning improves, CAD performance will likely also improve, particularly in identification of polyps most frequently missed by human observers, such as flat polyps. In fact, three of six polyps identified by OC but not by the interpreting radiologist in this study were flat polyps. As our understanding of flat polyps grows, it is reasonable to expect that this knowledge can be incorporated into CAD algorithms to improve sensitivity [28–30].

The limitations of this study include that it was performed at a single center in a predominantly screening population, although this population is precisely the one most likely to benefit from CAD as a second reader to assist in identifying precancerous polyps. CAD systems are not in widespread use,

although their use stands to increase given the recent USPSTF guidance. Although the number of CAD marks per patient is reasonable, a true measure of time spent evaluating these marks was not performed in this study. This study also only evaluated a single CAD system when reading on a single platform and may not be generalizable.

In conclusion, CAD performance in routine clinical practice is similar to previous retrospective evaluations, with excellent sensitivity and an acceptable false-positive rate. Furthermore, we have shown that CAD is being at least partially reimbursed in our clinical practice by third-party payers. The combination of good clinical performance and third-party reimbursement would suggest that use of CAD in CTC will likely increase in the future, especially in light of the recent positive USPSTF screening recommendation for CTC.

References

- Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonoscopy for the detection of advanced neoplasia. *N Engl J Med* 2007; 357:1403–1412
- U.S. Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. *JAMA* 2016; 315:2564–2575
- Lawrence EM, Pickhardt PJ, Kim DH, Robbins JB. Colorectal polyps: stand-alone performance of computer-aided detection in a large asymptomatic screening population. *Radiology* 2010; 256:791–798
- Regge D, Della Monica P, Galatola G, et al. Efficacy of computer-aided detection as a second reader for 6–9-mm lesions at CT colonography: multicenter prospective trial. *Radiology* 2013; 266:168–176 [Erratum in *Radiology* 2013; 266:1000]
- Petrick N, Haider M, Summers RM, et al. CT colonography with computer-aided detection as a second reader: observer performance study. *Radiology* 2008; 246:148–156
- Summers RM, Handwerker LR, Pickhardt PJ, et al. Performance of a previously validated CT colonography computer-aided detection system in a new patient population. *AJR* 2008; 191:168–174
- Summers RM, Yao JH, Pickhardt PJ, et al. Computed tomographic virtual colonoscopy computer-aided polyp detection in a screening population. *Gastroenterology* 2005; 129:1832–1844
- Mang T, Bogoni L, Salganicoff M, et al. Computer-aided detection of colorectal polyps in CT colonography with and without fecal tagging: a stand-alone evaluation. *Invest Radiol* 2012; 47:99–108
- Mang T, Peloschek P, Plank C, et al. Effect of computer-aided detection as a second reader in multidetector-row CT colonography. *Eur Radiol* 2007; 17:2598–2607
- Summers RM, Frenzt SM, Liu JM, et al. Conspicuity of colorectal polyps at CT colonography: visual assessment, CAD performance, and the important role of polyp height. *Acad Radiol* 2009; 16:4–14
- Summers RM, Liu JM, Rehani B, et al. CT colonography computer-aided polyp detection: effect on radiologist observers of polyp identification by CAD on both the supine and prone scans. *Acad Radiol* 2010; 17:948–959
- Dachman AH, Obuchowski NA, Hoffmeister JW, et al. Effect of computer-aided detection for CT colonography in a multireader, multicase trial. *Radiology* 2010; 256:827–835
- Regge D, Hassan C, Pickhardt PJ, et al. Impact of computer-aided detection on the cost-effectiveness of CT colonography. *Radiology* 2009; 250:488–497
- Pickhardt PJ. Screening CT colonography: how I do it. *AJR* 2007; 189:290–298
- Pickhardt PJ. Three-dimensional endoluminal CT colonography (virtual colonoscopy): comparison of three commercially available systems. *AJR* 2003; 181:1599–1606
- Pickhardt PJ, Taylor AJ, Kim DH, Reichelderfer M, Gopal DV, Pfau PR. Screening for colorectal neoplasia with CT colonography: initial experience from the 1st year of coverage by third-party payers. *Radiology* 2006; 241:417–425
- Shinners TJ, Pickhardt PJ, Taylor AJ, Jones DA, Olsen CH. Patient-controlled room air insufflation versus automated carbon dioxide delivery for CT colonography. *AJR* 2006; 186:1491–1496
- Buchach CM, Kim DH, Pickhardt PJ. Performing an additional decubitus series at CT colonography. *Abdom Imaging* 2011; 36:538–544
- Zalis ME, Barish MA, Choi JR, et al. CT colonography reporting and data system: a consensus proposal. *Radiology* 2005; 236:3–9
- Pickhardt PJ, Kim DH, Pooler BD, et al. Assessment of volumetric growth rates of small colorectal polyps with CT colonography: a longitudinal study of natural history. *Lancet Oncol* 2013; 14:711–720
- Pooler BD, Kim DH, Weiss JM, Matkowskyj KA, Pickhardt PJ. Colorectal polyps missed with optical colonoscopy despite previous detection and localization with CT colonography. *Radiology* 2016; 278:422–429
- Pyenson B, Pickhardt PJ, Sawhney TG, Berrios M. Medicare cost of colorectal cancer screening: CT colonography vs. optical colonoscopy. *Abdom Imaging* 2015; 40:2966–2976
- Pickhardt PJ, Hassan C, Laghi A, Zullo A, Kim DH, Morini S. Cost-effectiveness of colorectal cancer screening with computed tomography colonography: the impact of not reporting diminutive lesions. *Cancer* 2007; 109:2213–2221
- Trilisky I, Wroblewski K, Vannier MW, Horne JM, Dachman AH. CT colonography with computer-aided detection: recognizing the causes of false-positive reader results. *RadioGraphics* 2014; 34:1885–1905
- Koshkin VS, Hinshaw JL, Wroblewski K, Dachman AH. CAD-associated reader error in CT colonography. *Acad Radiol* 2012; 19:801–810
- Paul AB, Oklu R, Saini S, Prabhakar AM. How much is that head CT? Price transparency and variability in radiology. *J Am Coll Radiol* 2015; 12:453–457
- Fenton JJ, Lee CI, Xing G, Baldwin LM, Elmore JG. Computer-aided detection in mammography: downstream effect on diagnostic testing, ductal carcinoma in situ treatment, and costs. *JAMA Intern Med* 2014; 174:2032–2034
- Kim DH, Matkowskyj KA, Lubner MG, et al. Serrated polyps at CT colonography: prevalence and characteristics of the serrated polyp spectrum. *Radiology* 2016; 280:455–463
- Kim DH, Hinshaw JL, Lubner MG, Munoz del Rio A, Pooler BD, Pickhardt PJ. Contrast coating for the surface of flat polyps at CT colonography: a marker for detection. *Eur Radiol* 2014; 24:940–946
- Pickhardt PJ, Kim DH, Robbins JB. Flat (nonpolypoid) colorectal lesions identified at CT colonography in a US screening population. *Acad Radiol* 2010; 17:784–790